Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933232 | 0.91 | YTHDC1 (0.61) | YTHDC1ADORA2AADORA1TLR7NUDT1 | |
| SCHEMBL3955323 | 0.90 | YTHDC1 (0.56) | YTHDC1ADORA2AADORA1TLR7 | |
| SCHEMBL19633727 | 0.88 | YTHDC1 (0.54) | YTHDC1TLR7NUDT1PDE4APDE4B | |
| SCHEMBL2060130 | 0.86 | TLR7 (0.66) | YTHDC1ADORA2AADORA1TLR7NUDT1 | |
| SCHEMBL509407 | 0.86 | TLR7 (0.64) | YTHDC1ADORA2ATLR7NUDT1PDE4A | |
| SCHEMBL2058751 | 0.84 | TLR7 (0.50) | YTHDC1ADORA2ATLR7NUDT1PDE4A | |
| SCHEMBL3922033 | 0.84 | YTHDC1 (0.53) | YTHDC1ADORA2AADORA1TLR7NUDT1 | |
| SCHEMBL2060041 | 0.83 | TLR7 (0.67) | YTHDC1ADORA2AADORA1TLR7 | |
| SCHEMBL2058782 | 0.82 | YTHDC1 (0.55) | YTHDC1TLR7NUDT1PDE4APDE4B | |
| SCHEMBL12305136 | 0.82 | TLR7 (0.53) | TLR7PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | YTHDC1 4761/4885ADORA2A 991/4885ADORA1 1903/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | YTHDC1 4758/4885ADORA2A 917/4885ADORA1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.